Carol E. Peña
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Chronic Lymphocytic Leukemia Research, Cancer Genomics and Diagnostics, Renal cell carcinoma treatment, Hepatocellular Carcinoma Treatment and Prognosis
Most-Cited Works
- → Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma(2012)559 cited
- → Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma(2017)392 cited
- → First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas(2016)232 cited
- → Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial(2010)174 cited
- → Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis(2007)131 cited
- → Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer(2009)113 cited